Cardiac Biomarker Testing Market Report and Forecast 2025-2034

The global cardiac biomarker testing market size was valued at USD 4.68 Billion in 2024, driven by the increasing prevalence of cardiovascular diseases across the globe. The market size is anticipated to grow at a CAGR of 8.80% during the forecast period of 2025-2034 to achieve a value of USD 10.88 Billion by 2034 .

Cardiac Biomarker Testing: Introduction

The cardiac biomarker levels in blood are determined by cardiac biomarker test. When heart gets exposed to stress and experience damage from lack of oxygen, cardiac biomarkers become visible in blood. This could be the result of a heart attack. These levels, however, may be excessive for other causes. The concentrations of biomarkers are frequently used to determine the magnitude of a heart attack and the severity of your heart's damage immediately.

Global Cardiac Biomarker Testing Market Analysis

The increasing demand for cardiac biomarker testing globally is contributing to the market growth. The rising investments by the government and private healthcare institutions in the research and development of biomarkers to improve the quality of diagnosis, predictive analysis, and prognosis, is further propelling the global cardiac biomarker testing market share. These institutions are also focusing on novel biomarker tests, facilitating technological development in the cardiac biomarker testing, such as identification of biomarkers with the help of artificial intelligence. This will result in specific recognition of elements for biomarkers, along with fast, cheap readers, and disposable tests, to facilitate rapid testing at home.

WHO initiated a program called Global action plan for the prevention and control of NCDs 2013-2020, aiming to reduce the number of premature deaths from NCDs by 25% by 2025 through nine voluntary global targets. Such initiatives by global organizations are expected to result in positive outcomes.

WHO stated, “At least 50% of eligible people should receive drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes by 2025”. Due to all these initiatives and guidelines released by the government, the leading companies in the market are focusing on developing on new and more advanced devices and test kits to increase the convenience and reduce the time of diagnosis and enhanced treatment.

The increased awareness among the healthcare professionals and people in general has increased the use of advanced cardiac marker testing systems that enables early detection and diagnosis of various CVD conditions, including heart attack, myocardial infarction, acute coronary, syndrome, and heart failure, which further aids the cardiac biomarker testing market demand.

Global Cardiac Biomarker Testing Market Segmentations

Cardiac Biomarker Testing Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Testing Type

• Point of Care Testing (POCT)
• Laboratory Testing

Market Breakup by Technology

• Immunoassay
• Clinical Chemistry
• Molecular Diagnostics
• Others

Market Breakup by Biomarker Type

• Creatine Kinase (CK-MB)
• Troponins
• Myoglobin
• Natriuretic Peptides (BNP and NT-proBNP)
• Ischemia Modified Albumins
• Other Biomarkers

Market Breakup by Applications

• Myocardial Infraction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Other Applications

Market Breakup by End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Ambulatory Surgical Centers
• Research Institutes
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Global Cardiac Biomarker Testing Market Overview

The rising prevalence of cardiovascular disorders are greatly driving the market growth. According to World Health Organization WHO, Cardiovascular diseases (CVDs) accounts for estimated 17.9 million lives each year, major cause of death worldwide, further fuelling the global cardiac biomarker testing market growth. The increasing prevalence of cardiac disorders is justifying for the increasing demand of cardiac biomarker testing in the market contributing to the market growth. The geriatric population globally is also rising which is further propelling the market growth as aged people are more susceptible to heart diseases.

CVDs are a group of heart and blood vessels disorders that include coronary heart disease, cerebrovascular disease, and rheumatic heart disease, among other conditions. Referring to the data released by WHO, heart attacks and strokes accounts for nearly four out of five CVD deaths and one third of these deaths are premature in people under 70 years of age.

According to data released by WHO, People living in low- and middle-income countries often do not have the benefit of primary health care programmes for early detection and treatment of people with risk factors for CVDs.

The adaptation of sedentary lifestyle is also a major factor contributing to the increased number of CVDs globally. Consumption of alcohol, tobacco, lack of active sessions of exercise, and rising incidence of hypertension are also major factors impacting the health of people globally leading to CVDs even at younger age, escalating the market growth.

WHO says Health policies emphasizing on conducive environments in order to make appropriate health choices are essential for motivating people to adopt and sustain healthy behaviours. However, governments have started to roll out public policies and guidelines aiming to reduce the cases of CVDs and motivating people to engage in healthy lifestyles.

The increasing awareness about the importance of early diagnosis of CVDs is also directly aiding the cardiac biomarker testing market share. WHO suggests, identification of CVDs on early basis and ensuring early treatment can significantly prevent premature deaths caused by cardiovascular disorders.

Cardiac Biomarker Testing Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Beckman Coulter, Inc. (Danaher Corporation)
• bioMérieux SA
• Ortho Clinical Diagnostics
• Becton, Dickinson and Company (BD)
• Thermo Fisher Scientific Inc.
• Randox Laboratories Ltd.
• Bio-Rad Laboratories, Inc.
• Singulex Inc.
• Abbott
• LSI Medience Corporation
• Trivitron Healthcare
• Qingdao Rich Biotechnology Co., Ltd.
• Werfen
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Guangzhou Wondfo Biotech Co., Ltd.
• Abnova Corporation
• Merck KGaA

This product will be delivered within 3-5 business days.